| PARTNER | This data is not available for free |
| AGREEMENT |
In March 2004, Co. announced an amendment to its agreement with Partner for the co-promotion of brand levalbuterol HCl inhalation solution, a beta-agonist, which is now indicated for the treatment or prevention of bronchospasm in patients 6 years of age or older with reversible obstructive airway disease, such as that which occurs in patients with asthma or COPD. Under the terms of the amendment, the agreement will be terminated effective December 31, 2004. Partner co-promotes drug primarily to pediatricians in the U.S. in exchange for a commission on pediatric product sales, and Co.'s sales force promotes drug to pediatricians as well as allergists, pulmonologists and primary care physicians throughout the U.S. Partner will continue to co-promote drug to pediatricians and targeted primary care physicians through December 31, 2004. Co. is credited with all sales and Partner receives a commission on pediatric sales. Each company is responsible for its own selling expenses |
| COMPANY | This data is not available for free |
|
Want more information ? Interested in the hidden information ? Click here and do your request. |